The microneedles deliver medication directly between the choroid and sclera to treat retinal disease and are hoped to be more effective than eye drops and less invasive than hypodermic needles or surgery. Trials of its product CLS1001 are expected to begin this quarter.
More Articles on Ophthalmology:
Dr. Yingbin Fu of Moran Eye Center Receives National Eye Institute Award
Toyos Clinic in Memphis Merges With Ophthalmology Management of Nashville
Coastal Bend Eye Center in Texas Hires New Optician
